Columbia Partners L L C Investment Management Has $4.45 Million Stake in AxoGen, Inc. (AXGN)
Columbia Partners L L C Investment Management decreased its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 19.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 230,118 shares of the medical equipment provider’s stock after selling 56,028 shares during the quarter. Columbia Partners L L C Investment Management owned about 0.69% of AxoGen worth $4,452,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of AxoGen by 9.0% during the second quarter. Vanguard Group Inc. now owns 1,223,069 shares of the medical equipment provider’s stock valued at $20,486,000 after acquiring an additional 101,245 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of AxoGen by 293.9% during the third quarter. Bank of New York Mellon Corp now owns 631,563 shares of the medical equipment provider’s stock valued at $12,222,000 after acquiring an additional 471,209 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of AxoGen by 238.7% during the second quarter. Russell Investments Group Ltd. now owns 611,678 shares of the medical equipment provider’s stock valued at $10,245,000 after acquiring an additional 431,057 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of AxoGen by 1.5% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 568,124 shares of the medical equipment provider’s stock valued at $9,516,000 after acquiring an additional 8,608 shares during the period. Finally, State Street Corp boosted its holdings in shares of AxoGen by 19.6% during the second quarter. State Street Corp now owns 438,641 shares of the medical equipment provider’s stock valued at $7,350,000 after acquiring an additional 71,752 shares during the period. 67.44% of the stock is owned by institutional investors.
In other AxoGen news, Director Robert James Rudelius sold 16,143 shares of the business’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $18.00, for a total value of $290,574.00. Following the sale, the director now directly owns 43,273 shares in the company, valued at $778,914. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.33% of the stock is currently owned by insiders.
Shares of AxoGen, Inc. (AXGN) traded down $2.30 during midday trading on Friday, hitting $22.60. 1,615,800 shares of the company were exchanged, compared to its average volume of 206,372. AxoGen, Inc. has a fifty-two week low of $8.05 and a fifty-two week high of $25.15. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93.
AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The business had revenue of $16.05 million for the quarter, compared to analysts’ expectations of $15.55 million. The firm’s quarterly revenue was up 43.2% on a year-over-year basis. analysts predict that AxoGen, Inc. will post -0.31 earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $18.00 price target on shares of AxoGen in a report on Monday, August 21st. Leerink Swann restated an “outperform” rating and set a $23.00 price objective (up from $22.00) on shares of AxoGen in a research note on Saturday, September 30th. BidaskClub cut shares of AxoGen from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Finally, Roth Capital restated a “buy” rating and set a $21.00 price objective (up from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. AxoGen presently has an average rating of “Buy” and an average price target of $18.00.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.